NEW YORK (GenomeWeb) – Ginkgo Bioworks today announced it has acquired several assets from Warp Drive Bio, a subsidiary of Revolution Medicines, including its genome mining platform.
Warp Drive's bioinformatics technology sifts through microbial genome databases to uncover potential antibiotics. Its genomic database includes more than 135,000 bacterial strains.
Under the terms of the deal, Ginkgo will obtain Warp Drive's genomic sequence collection and bioinformatics software. Warp Drive's genome mining team will also move to Ginkgo's headquarters in Boston.